Abstract Details

Title Implementation of Medication Therapy Disease Management Pharmacist for Multiple Sclerosis Patients in a Community Based Neurology Setting

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 349

Objective To assess the role of specialized medication therapy disease management (MTDM) pharmacists and the utility of electronic medical record (EMR) dashboard for surveillance and safety labs in multiple sclerosis (MS) patients.

Background Geisinger is an accountable care organization striving for patient care and safety. MS is a chronic demyelinating condition usually treated with a disease-modifying therapy (DMT). This program was implemented in our department in 2014 to improve compliance and prevent side effects from MS DMTs.

Design/Methods 3 MTDM pharmacists are managing 1700 MS patients across the system. A specialized dashboard was developed, which gets information from the EMR, containing the demographic and clinical data. Once a new consult order is placed in EMR, it is routed to the appropriate pharmacist. The consult order contains preferred DMT and any contraindications for the use of certain other DMT’s. The pharmacist follows up on the different MS mimic labs and, after consulting with the MS neurologist formulates a follow-up telephonic visit to discuss the treatment options most suitable for the MS patients.

Results 1734 MS patients were identified as being managed by the MTDM program in our department. 1240 (71%) patients were female, while 1198 (69%) of the patients were in the age range between 40-64 years, while 329 (19%) were between the 18-39 age group. 833 (48%) patients were on infusions, 492 (28%) were on oral medications, and 409 (24%) were on platform medications.

Conclusions With the introduction of newer DMT’s it is even more imperative that the MS patients on DMTs need to be monitored to prevent side effects that can be life-threatening. Another important consideration is to avoid unnecessary ER visits from specific side effects of these DMTs and pseudo-relapses. Overall, the collaboration with MTDM pharmacist has increased patient safety, tolerability, and compliance of DMTs.

Authors/Disclosures
Muhammad Taimur A. Malik, MD (St Lukes) PRESENTER	Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD serono. The institution of Dr. Malik has received research support from National MS Society .
Melissa Sartori, PharmD (Geisinger Neurology)	Dr. Sartori has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Megan E. Esch, MD (Geisinger Medical Center)	The institution of Dr. Esch has received research support from PCORI.

��ɫ��

��ɫ��